Publications by authors named "Sephy Philip"

Claim this Profile
H
Hypertriglyceridemia in cardiac rehabilitation-A residual risk worth targeting?
Rahul Aggarwal, John R Nelson, Sephy Philip

Int J Cardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of product label vs real-world safety data from branded icosapent ethyl users: A select analysis utilizing MarketScan data.
John R Nelson, Richard A Hansen, Handrean Soran, Nilima Justice, Om P Ganda, Sephy Philip

J Clin Lipidol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethyl.
Peter P Toth, John R Nelson, Handrean Soran, Om P Ganda, Nathan D Wong, Sephy Philip

Front Cardiovasc Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States.
William S Weintraub, Deepak L Bhatt, Zugui Zhang, Sarahfaye Dolman, William E Boden, Sephy Philip

J Am Heart Assoc· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: 'Cardiovascular outcomes of ethyl eicosapentaenoic acid in diabetes mellitus: a meta-analysis'.
Sephy Philip

Ann Med Surg (Lond)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins.
Sarah Leatherman, Ryan Ferguson, Cynthia Hau, Kelly Harrington, Craig Granowitz, Sephy Philip

Front Cardiovasc Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl.
Catherine G Derington, Adam P Bress, Jennifer S Herrick, Wenjun Fan, Nathan D Wong, Sephy Philip

Am J Prev Cardiol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global assessment improves risk stratification for major adverse cardiac events across a wide range of triglyceride levels: Insights from the KP REACH study.
Jeffrey R Wagner, Jesse K Fitzpatrick, Jingrong Yang, Sue Hee Sung, Amanda R Allen, Sephy Philip

Am J Prev Cardiol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study.
Andrew P Ambrosy, Jingrong Yang, Sue Hee Sung, Amanda R Allen, Jesse K Fitzpatrick, Sephy Philip

J Am Heart Assoc· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between triglycerides and incident cardiovascular disease: What is "optimal"?
Tsion Aberra, Eric D Peterson, Neha J Pagidipati, Hillary Mulder, Daniel M Wojdyla, Sephy Philip

J Clin Lipidol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world analyses of patients with elevated atherosclerotic cardiovascular disease risk from the Optum Research Database.
Peter P Toth, Michael Hull, Craig Granowitz, Sephy Philip

Future Cardiol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE).
Andrew P Ambrosy, Umar I Malik, Rachel C Thomas, Rishi V Parikh, Thida C Tan, Sephy Philip

Am Heart J· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]).
Nathan D Wong, Wenjun Fan, Sephy Philip, Craig Granowitz, Peter P Toth

Am J Cardiol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial).
Adam J Nelson, Ann Marie Navar, Hillary Mulder, Daniel Wojdyla, Sephy Philip

Am J Cardiol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies.
Brian Olshansky, Mina K Chung, Matthew J Budoff, Sephy Philip, Lixia Jiao

Eur Heart J Suppl· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014.
Wenjun Fan, Sephy Philip, Peter P Toth, Craig Granowitz, Wong Nathan D

Am J Prev Cardiol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy.
Brian C Case, Adam P Bress, Paul Kolm, Sephy Philip, Jennifer S Herrick

J Clin Lipidol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200-499 mg/dL) Are Significant Predictors of Hospitalization for New-Onset Kidney Disease: A Real-World Analysis of High-Risk Statin-Treated Patients.
Peter P Toth, Sephy Philip, Michael Hull, Craig Granowitz

Cardiorenal Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007-2014.
Wenjun Fan, Sephy Philip, Peter P Toth, Craig Granowitz, Nathan D Wong

Cardiol J· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007-2014.
Wenjun Fan, Sephy Philip, Craig Granowitz, Peter P Toth, Nathan D Wong

Cardiol Ther· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200-499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients.
Peter P Toth, Sephy Philip, Michael Hull, Craig Granowitz

Vasc Health Risk Manag· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014.
Wenjun Fan, Sephy Philip, Craig Granowitz, Peter P Toth, Nathan D Wong

Diabetes Care· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis.
Peter P Toth, Sephy Philip, Michael Hull, Craig Granowitz

Clin Cardiol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients.
Peter P Toth, Sephy Philip, Michael Hull, Craig Granowitz

Mayo Clin Proc· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis.
Peter P Toth, Craig Granowitz, Michael Hull, Amy Anderson, Sephy Philip

Lipids Health Dis· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis